Cost optimization strategies CagriSema is expensive but manageable
Allison Whitten AstraZeneca reports mixed Phase 3 results across oncology and rare disease AstraZeneca reported mixed late-stage clinical results, with its Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin meeting its primary endpoint in patients with previously treated advanced gastric cancer, while rare disease therapy Ultomiris missed the primary endpoint in a Phase 3 trial for thrombotic microangiopathy following haematopoietic stem cell transplantation (HSCT-TMA)
In this laboratory study, measurable follicle elongation was observed within 12 days
Verify current product details on supplier website
These effects occur without elevating IGF-1 or affecting carbohydrate metabolism, differentiating it from full-length HGH in terms of safety and selectivity
Another 48-day phase 2a study in Japanese participants with uncontrolled T2D reveals mean weight loss of 2.1%, 3.3%, 3.3%, and 0.8% for the groups administered 100 mcg, 200 mcg, 300 mcg and placebo, respectively (102)